We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma.
- Authors
Batchelor, Tracy T; Duda, Dan G; di Tomaso, Emmanuelle; Ancukiewicz, Marek; Plotkin, Scott R; Gerstner, Elizabeth; Eichler, April F; Drappatz, Jan; Hochberg, Fred H; Benner, Thomas; Louis, David N; Cohen, Kenneth S; Chea, Houng; Exarhopoulos, Alexis; Loeffler, Jay S; Moses, Marsha A; Ivy, Percy; Sorensen, A Gregory; Wen, Patrick Y; Jain, Rakesh K
- Abstract
Glioblastoma is an incurable solid tumor characterized by increased expression of vascular endothelial growth factor (VEGF). We performed a phase II study of cediranib in patients with recurrent glioblastoma.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Vol 28, Issue 17, p2817
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2009.26.3988